F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis

Haslerud, Torjan; Brauckhoff, Katrin; Reisæter, Lars Anders Rokne; Lein, Tor Eiliv; Heinecke, A.; Varhaug, Jan Erik; Biermann, Martin

doi:10.1177/0284185115594645

Cited by 62 publications

(26 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the first meta-analysis that also addresses the comparison between PET/CT and conventional imaging in thyroid cancer. Haslerud et al [43] published a recent meta-analysis including patients with recurrent differentiated thyroid cancer. The authors showed a sensitivity and specificity for PET and PET/CT of 79.4% (CI 73.9–84.1%) and 79.4% (CI 71.2–85.4%).…”

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

Background: Positron emission tomography (PET) and PET/CT are functional imaging methods that are widely used in diagnostic procedures in oncology. Objectives: The objective of this study was to assess the patient-relevant benefit of PET or PET/CT in patients with thyroid cancer based on a literature review and meta-analysis. Methods: A systematic review including studies that had been published until December 2013 was performed. To be included, studies had to prospectively investigate patients with thyroid cancer in a clinical setting of staging, restaging, or diagnosing tumour recurrence. Results: Out of 3,506 potentially relevant articles, 29 studies were included. No study directly evaluated the benefits of PET. Twenty-eight studies dealt with the diagnostic accuracy of PET or PET/CT, and 1 study evaluated the prognostic value of PET/CT. The authors showed that a positive result of PET/CT in restaging patients with differentiated thyroid cancer yielded a significant decrease in overall survival (hazard ratio, HR 5.01, CI 3.41–6.62). In patients with suspected recurrence of differentiated thyroid cancer, meta-analysis showed higher sensitivity of PET (89.7%, CI 78–99%) and PET/CT (94.3%, CI 87–97%) compared with conventional imaging (65.4%, CI 32–88%) and comparable results for specificity. Due to the low numbers of studies and patients, meta-analyses on medullary carcinoma did not produce meaningful results. Conclusion: The patient-relevant benefits of PET or PET/CT in thyroid cancer could not be evaluated satisfactorily based on the included studies. It remains unclear whether higher diagnostic test accuracy leads to changes in therapeutic strategies and better patient-relevant outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Так, активно изучается значение мутации гена BRAF и экспрессии NIS, что исполь-зуется в качестве дооперационных диагностических маркеров при ВДР ЩЖ [3]. В последние годы стали появляться немногочисленные зарубежные работы по исследованию экспрессии глюкозного транспортера (GLUT-1) и его взаимосвязи с дифференцировкой раз-личных видов опухолей [4][5][6][7]. Есть ряд исследований, посвященных определению GLUT-1 в клетках рака щитовидной железы, при этом описывается увеличе-ние экспрессии GLUT-1 в клетках низкодифферен-цированного и анапластического рака щитовидной железы [4,5,7], а также прямая зависимость между значением GLUT-1 и эффективностью ПЭТ-КТ [3].…”

Section: значение экспрессии глюкозного транспортера в прогнозе теченunclassified

Prognostic Value of Glut-1 Expression in the Highly Differentiated Thyroid Cancer

Semenov¹,

Борискова²,

Панкова³

et al. 2018

VESTNIK KHIRURGII IMENI I.I.GREKOVA

View full text Add to dashboard Cite

В в е д е н и е. Высокодифференцированный рак щитовидной железы (ВДР ЩЖ) составляет 90-95 % всех случаев рака щитовидной железы [1]. Заболе-ваемость ВДР ЩЖ в нашей стране на сегодняшний день составляет более 10,5 тыс. человек в год [1]. Хотя отличительной особенностью ВДР ЩЖ явля-ется очень медлен ный рост и хороший прогноз при своевременном выявлении и правильно проведен-ном лечении, у 20 % больных встречается перси-стенция заболевания и рецидивирование более чем через 5 лет после операции [1]. В последние годы от-мечается тенденция к снижению агрессивной хирур-гической тактики лечения ВДР ЩЖ. Так, расшири-лись показания к выполнению органосохраняющих операций [2,3]. Однако несмотря на относительно благоприятный прогноз ВДР ЩЖ, иногда наблюда-ют прогрессию заболевания даже при проведении имеющейся в клинических рекомендациях тактики лечения. Исходя из этого, складывается мнение, что пациенты с ВДР ЩЖ представляют разнородную группу с различным прогнозом течения, и, соот-ветственно, тактика лечения должна носить инди-видуальный характер в зависимости от прогноза течения заболевания. Таким образом, актуальным становится прогнозирование течения ВДР ЩЖ для оптимизации тактики хирургического лечения. OBJECTIVE. Analysis of GLUT1 levels as a prognostic marker for highly differentiated thyroid carcinoma. MATERIAL AND METHODS. The expression levels of GLUT-1, NIS, thyroglobulin and the presence of BRAF mutation were analyzed in 32 patients with highly differentiated thyroid cancer from the Department of Surgical Endocrinology at the Research Institute for Surgery and Emergency Medicine of "Pavlov First Saint Petersburg State Medical University". RESULTS. There was a trend to increased levels of GLUT-1 in patients with regional or intra-organ metastases or peripheral invasion. This suggests that increased expression of GLUT-1 is found in proliferatively active cells. In our study, the expression level of GLUT-1 was independent of the level of NIS, thyroglobulin and the presence of BRAF mutation. Thus, the level of expression of GLUT-1 can be considered as an independent factor of the prognosis of the course of highly differentiated thyroid carcinoma. CONCLUSION. The level of expression of GLUT-1 could potentially be used as a prognostic marker in highly differentiated thyroid cancer.

show abstract

“…Thyroid cancer is the most common malignancy of the endocrine system [1–3]. Well differentiated thyroid cancer (WDTC) is the most common of all histologic subtypes of thyroid cancer, accounting about 80–85% of all thyroid malignancies [4].…”

Section: Introductionmentioning

confidence: 99%

“…Unlike more aggressive subtypes like anaplastic and medullary thyroid carcinomas, WDTC generally has a favorable prognosis. However 20–30% of WDTC recurs, and 7% of patients with recurrent disease will die within 10 years of initial diagnosis [1,4,5]. …”

Section: Introductionmentioning

confidence: 99%

“…Following initial treatment with total thyroidectomy and radioactive iodine therapy (RIT), serum thyroglobulin (Tg) level becomes a reliable marker for persistent or recurring disease in the absence of anti-thyroglobulin antibodies [1,4]. In the case of a rising Tg level with a negative neck ultrasound, clinicians often consider cross sectional imaging [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC)

Mudalegundi

Switchenko

et al. 2016

Thyroid Disorders Ther

View full text Add to dashboard Cite

Background Positron emission tomography/computed tomography is suggested to have a role in detection of iodine negative recurrence in well differentiated thyroid cancer. The aim of this study is to identify role of different imaging modalities in the management of well differentiated thyroid cancer. Methods We reviewed 900 well differentiated thyroid cancer patients after post-thyroidectomy who underwent recombinant human thyroid stimulating hormone stimulated Sodium Iodide I 131 imaging. Out of 900 patients, 74 had positron emission tomography/computed tomography. Multivariate analysis was performed by controlling positron emission tomography/computed tomography, Sodium Iodide I 131 scan, neck ultrasonography, age, sex, primary tumor size, stage, histology, thyroglobulin. Patients were grouped according to results of Sodium Iodide I 131 scan and positron emission tomography/computed tomography. Results Positron emission tomography/computed tomography was positive in 23 of 74 patients. The sensitivity for positron emission tomography was 11/11(100%), the specificity was 51/63 (81.0%), the positive predictive value was 11/23 (47.8%), and the negative predictive value was 51/51 (100%). The sensitivity for the neck ultrasonography was 4/8 (50%), the specificity was 53/60 (88.3%), positive predictive value was 4/11 (36.4%), and negative predictive value was 53/57 (93.0%). 50% of patients who had Sodium Iodide I 131 negative scan and positive positron emission tomography/computed tomography had a change in management. Thirty-six percent with positive neck ultrasonography had a change in management. Out of 11 recurrences, 6 had distant metastatic disease, and 5/11 had regional nodal disease. Neck ultrasonography showed nodal metastasis in 4/5 (80%). Conclusion Positron emission tomography/computed tomography altered management in the presence of a high thyroglobulin level and a negative Sodium Iodide I 131 scan. Neck ultrasonography should be the first line of imaging with rising thyroglobulin levels. Positron emission tomography/computed tomography should be considered for cases with high thyroglobulin levels and normal neck ultrasonography to look for distant metastatic disease.

show abstract

F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis

Cited by 62 publications

References 44 publications

Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis

Prognostic Value of Glut-1 Expression in the Highly Differentiated Thyroid Cancer

Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC)

Contact Info

Product

Resources

About